Those in the low NLR had better OS (p = 0.023) after adjusting for estrogen receptor (ER) status, age at recurrence, (neo)adjuvant chemotherapy, surgical resection of metastatic disease, metastatic organ number, DFI, and liver metastasis (Table 3). This evidence concerns the gene ESR1 and metastatic neoplasm.